Summary

Hyperglycemia is a common condition among cardiac surgery patients, and it occurs in approximately half of all patients following surgery. Although it is agreed that controlling hyperglycemia reduces risk of organ failure, infection, and mortality, the ideal target range for blood glucose in the perioperative period remains unknown. This article discusses the GLUCO-CABG trial [NCT01792830], which examined if intensive glucose control while the patient is in the ICU following coronary artery bypass grafting can improve outcomes.